Tempus AI

Tempus AI is a precision medicine platform that turns clinical and molecular data into AI-driven insights for cancer care.

Overview

Tempus AI built one of the largest libraries of matched clinical and molecular data in oncology, then layers machine learning on top so physicians and life-science teams can act on it. Its genomic sequencing reports help clinicians match patients to targeted therapies and clinical trials, while the data platform lets researchers query de-identified records at scale. The company also licenses AI models for diagnostic imaging and clinical decision support. Hospitals, academic centers and pharmaceutical companies use Tempus to shorten the path from test result to treatment decision.

Key Features

• Next-generation genomic sequencing reports with therapy and trial matching
• Tempus ONE multimodal data library linking clinical records to molecular profiles
• AI-enabled pathology and radiology models for diagnostic support
• Real-world data access for oncology research and trial design
• Clinical decision support embedded in provider workflows
• Patient engagement tools that collect outcomes and consented data

Pricing

Tempus AI operates on enterprise agreements with health systems, labs and pharma customers. Sequencing tests are billed through clinical channels, while data and platform access is priced per contract.

Who Is It For

Oncologists, molecular pathologists, hospital precision-medicine programs and pharmaceutical R&D teams. It fits institutions that want both a clinical testing partner and a data asset for research.

FAQ

Is Tempus AI free to use?

No. Tempus is a clinical and enterprise platform; pricing is negotiated with each health system or life-science customer.

Does Tempus AI offer an API?

Yes. Enterprise clients can access Tempus data and analytics through structured data feeds and API integrations.

How does Tempus AI compare to alternatives?

Unlike standalone sequencing vendors, Tempus pairs molecular testing with an AI-ready clinical data library, which is why research teams often choose it over pure lab providers.

Practical Use Cases

Oncologists order Tempus sequencing to find actionable mutations for late-stage patients, then use trial-matching views to identify open studies within travel distance. Tumor boards pull Tempus reports into multidisciplinary review to weigh targeted therapy options against guidelines. Pharma teams query the de-identified data library to size patient populations, select biomarkers and design trial inclusion criteria. Hospital precision-medicine programs build repeatable workflows on top of Tempus results, from consent through post-test counseling and longitudinal outcomes capture.

Limitations & Alternatives

Tempus is oncology-centric and enterprise-priced, so it is not a fit for small practices or non-cancer diagnostics. Turnaround and reimbursement vary by test and payer, and organizations with existing molecular programs may find integration work non-trivial. Foundation Medicine (Roche) is the closest competitor in comprehensive genomic profiling, while smaller labs and imaging-focused AI vendors address narrower slices of the same care pathway.

Integrations & Deployment

Tempus integrates with hospital EHRs and laboratory information systems through established clinical interfaces, so sequencing orders and results move through existing oncology workflows rather than parallel processes. Deployment usually begins with a defined service line such as solid-tumor profiling, then expands as governance, tumor boards and reimbursement pathways mature. The data platform side is accessed through secure enterprise connections arranged during onboarding, with support for de-identified research environments. Because outputs feed real treatment decisions, implementations include validation phases, clinician training and consent workflows; organizations typically assign a clinical champion plus IT resources to keep integrations healthy. Cloud infrastructure handles storage and computation, and enterprise agreements cover security review, compliance documentation and ongoing model updates.